GlaxoSmithKline

HUTCHMED signed an exclusive global development and licensing agreement with a GSK subsidiary for HMPL-A830, a KRAS‑EGFR‑directed antibody‑drug conjugate, with a potential total value of up to $1.295 billion. HUTCHMED will receive $110 million upfront and can earn up to $1.185 billion in milestones plus tiered royalties; GSK receives rights outside mainland China, Hong Kong, Macau and Taiwan, while HUTCHMED retains those territories. The deal is seen as validation of the ATTC platform and foresees the start of a global Phase I program in H2 2026. The news, together with a recent conditional approval of fanregratinib in China, drove an intraday share rise of about 14% to $13.95. » Więcej na de.investing.com

GSK presented positive phase‑2 results for its mRNA influenza vaccine at a scientific conference; the vaccine elicited stronger immune responses in younger and older adults compared with licensed inactivated vaccines and was well tolerated. The company plans a phase‑3 efficacy study in September that will for the first time test an mRNA flu vaccine against HA and NA. If successful, GSK would move into direct competition with Moderna in the mRNA flu vaccine market. » Więcej na deraktionaer.de

The US drug regulator FDA is giving priority review to GSK’s colorectal cancer drug Jemperli (dostarlimab) and has set a review deadline through February. Jemperli also qualifies for the priority voucher program, which can shorten the approval process. GSK expects the drug could make chemotherapy, radiation and surgery unnecessary for some patients; the company also reported approval of Hibsago in Japan for chronic hepatitis B. GSK’s stock traded slightly weaker during the session. » Więcej na finanzen.net

GSK has appointed Roy Jakobs, currently CEO of Royal Philips, effective Sunday as an independent, non-executive member of the board. Jakobs, CEO of Philips since 2022 and with the company since 2010, will receive the usual annual fee of £122,258 and must hold shares worth twice that amount. The appointment was recommended by the nomination and corporate governance committee; after the decision the board has 13 members. » Więcej na de.investing.com

Nuvalent shares climbed to an all-time high of $123.7 and are only 1% below the 52-week high after investors showed confidence in the biotech. GSK has made a $10.6 billion takeover offer ($124 per share) for Nuvalent’s oncology assets, including candidates Zidesamtinib and Neladalkib. Valuation checks suggest the stock may be trading above its fair value, and analysts such as UBS and Bernstein have adjusted their ratings/price targets after the takeover news to neutral/market perform and $124, respectively. Despite high liquidity relative to debt, Nuvalent remains unprofitable as investors monitor further developments. » Więcej na de.investing.com